中国医院用药评价与分析2025，Vol.25Issue(2)：211-214,4.DOI:10.14009/j.issn.1672-2124.2025.02.018
葡萄糖激酶激活剂多格列艾汀的遴选评价
Selection and Evaluation of Glucokinase Activator Doglietine
摘要
Abstract
OBJECTIVE:To perform rapid selection and evaluation of doglietine,the first glucokinase activator in the world,based on the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition),so as to provide reference for rational drug introduction in medical institutions.METHODS:The evaluation method of the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition)was applied to perform the comprehensive clinical evaluation of pharmaceutical properties,efficacy,safety,economy and other attributes of doglietine(including medical insurance status,essential drugs status,storage conditions,drug validity,global use and corporate reputation).RESULTS:Doglietine scored 25 points for pharmaceutical properties,15 points for efficacy,18.5 points for safety,8.2 points for economy and 3.5 points for other attributes,with a total score of 70.2 points.Doglietine had a unique mechanism of action,high safety and economy.However,more clinical research evidence was needed to improve its guideline recommendation status.The recommendation level of the drug was"strong recommendation".CONCLUSIONS:This health technology evaluation provides technical experience for medical institutions to perform new drug selection evaluation,and also provides decision support for medical institutions to select glucokinase activator doglietine.关键词
葡萄糖激酶激活剂/多格列艾汀/数字化遴选评价/药物选择/合理用药Key words
Dlucokinase activator/Doglietine/Digital selection and evaluation/Drug selection/Rational drug use分类
医药卫生引用本文复制引用
朱晓冉,田冬冬,张玥,冯运佳,蔡玥,董占军..葡萄糖激酶激活剂多格列艾汀的遴选评价[J].中国医院用药评价与分析,2025,25(2):211-214,4.基金项目
河北省 2023 年度医学科学研究课题计划(No.20230423) （No.20230423）
